Genetic Testing

In Office Genetic Testing

We are the pioneers in diagnostic testing for breast and other hereditary cancers. Today, the 35-gene Myriad myRisk® Hereditary Cancer test is keeping us at the forefront of scientific innovation in molecular diagnostics.

Recent evidence suggests up to 15% of breast cancers may be associated with a genetic predisposition. By screening for genes such as BRCA1 and BRCA2 we can determine if an individual may have a significantly increased chance to develop cancer in the future. Individuals who carry a mutation in either the BRCA1 or BRCA2 gene have a condition called Hereditary Breast and Ovarian Cancer (HBOC) syndrome, which is associated with an 87 percent risk of developing breast cancer by age 70. Mutation carriers who have already been diagnosed with cancer also have a significantly increased risk of developing a second cancer. By offering Myriad’s MyRisk genetic test we can identify patients with who have mutations in BRCA1, BRCA2, and many other genes.

Who should be tested for a BRCA1 or BRCA2 gene mutation with myriad myrisk

A patient’s personal or family history indicates that he/she may be at increased risk to have a genetic mutation that increases their risk of cancer. Genetic testing provides the most accurate means of assessing cancer risk. Knowing the potential risk can help you make better, more informed decisions about your health, before the onset of cancer or before a second cancer has developed.

Genetic testing for hereditary breast and ovarian cancer with the Myriad myRisk Hereditary Cancer panel should be considered if:*

The Patient:
  • Has had breast cancer at ANY age
  • Has had ovarian cancer at any age
  • Has had triple negative breast cancer at any age
  • Is male and has had breast cancer at any age
  • Is of Ashkenazi Jewish descent and has a personal or family history of breast, ovarian, prostate or pancreatic cancer
The Patient’s Family:
  • Has a relative with breast cancer younger than 50 years.
  • Has had two breast cancers in the same person or on the same side of the family
  • Has had someone diagnosed with triple negative breast cancer at any age
  • Has had pancreatic cancer at any age
  • Has three or more family members with breast cancer on the same side of the family
  • Has had a previously identified BRCA1, BRCA2 or other gene mutation in the family

Using the results of hereditary cancer testing to reduce Breast Cancer Risk

If hereditary cancer genetic testing confirms the presence of a BRCA1 or or BRCA2 mutation or another gene associated with breast cancer risk, the following medical management options may help to reduce your patient’s breast cancer risk and may either prevent or delay the onset of cancer or detect cancer at an earlier, more treatable stage, when outcomes are better:

  • Increased surveillance for breast cancer
  • Increased surveillance for ovarian cancer
  • Increased surveillance for other cancers
  • Risk-reducing medications
  • Prophylactic surgery, such as mastectomy or oophorectomy

Using Hereditary Cancer testing results to improve Patient Care

Hereditary cancer gene panel testing results can assist you in developing personalized medical management plans that can help you:

  • Maximize patient care and increase clinical efficiency by providing increased surveillance and other interventions for patients with a BRCA1, BRCA2 or other gene mutation.
  • Improve outcomes and reduce medical costs through earlier diagnosis and treatment of cancer if it develops.
  • Counsel patients and their families on the underlying causes of the pattern of breast, ovarian and/or other cancer in their family and how this might affect their cancer risk.
  • Avoid unnecessary interventions for family members who do not test positive for the mutation.

*Assessment criteria are based on individual medical society guidelines.
**HBOC-associated cancers are breast (including DCIS), ovarian, prostate and pancreatic.

Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.